Barr's bid for biogenerics line seen as risky by some

09/16/2006 | CNNMoney

Stock analysts are labeling as "risky" the $2.5 billion bid Barr Pharmaceuticals has made for the Croatian Pliva to get access to its biogenerics drug line. Some called the bid by the U.S. generics maker "speculative" for an industry still in early stages of development. Competing bidder Actavis, of Iceland, has until Sept. 27 to top Barr's bid.

View Full Article in:

CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ